Afficher la notice abrégée

dc.contributor.authorCooper, N.A.M.
dc.contributor.authorSaeed Khan, Khalid 
dc.date.accessioned2023-06-12T09:20:54Z
dc.date.available2023-06-12T09:20:54Z
dc.date.issued2023-04
dc.identifier.citationCooper, N. A. M., Rivas, C., Munro, M. G., Critchley, H. O. D., Clark, T. J., Matteson, K. A., ... & Khan, K. (2023). Standardising outcome reporting for clinical trials of interventions for heavy menstrual bleeding: Development of a core outcome set. BJOG: An International Journal of Obstetrics & Gynaecology.[DOI: 10.1111/1471-0528.17473]es_ES
dc.identifier.urihttps://hdl.handle.net/10481/82335
dc.description.abstractObjective: To develop a core outcome set for heavy menstrual bleeding (HMB). Design: Core outcome set (COS) development methodology described by the COMET initiative. Setting: University hospital gynaecology department, online international survey and web-based international consensus meetings. Population or sample: An international collaboration of stakeholders (clinicians, patients, academics, guideline developers) from 20 countries and 6 continents. Methods: Phase 1: Systematic review of previously reported outcomes to identify potential core outcomes. Phase 2: Qualitative studies with patients to identify outcomes most important to them. Phase 3: Online two-round Delphi survey to achieve consensus about which outcomes are most important. Phase 4: A consensus meeting to finalise the COS. Main outcome measures: Outcome importance was assessed in the Delphi survey on a 9-point scale. Results: From the ‘long list’ of 114, 10 outcomes were included in the final COS: subjective blood loss; flooding; menstrual cycle metrics; severity of dysmenorrhoea; number of days with dysmenorrhoea; quality of life; adverse events; patient satisfaction; number of patients going on to have further treatment for HMB and haemoglobin level. Conclusions: The final COS includes variables that are feasible for use in clinical trials in all resource settings and apply to all known underlying causes of the symptom of HMB. These outcomes should be reported in all future trials of interventions, their systematic reviews, and clinical guidelines to underpin policy.es_ES
dc.description.sponsorshipAcademy of Medical Sciences (AMS)es_ES
dc.description.sponsorshipNational Institute for Health Research (NIHR)es_ES
dc.description.sponsorshipBeatriz Galindo (senior modality) Programme Grantes_ES
dc.language.isoenges_ES
dc.publisherWyleyes_ES
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectAUBes_ES
dc.subjectCore outcome setes_ES
dc.subjectHeavy menstrual bleedinges_ES
dc.titleStandardising outcome reporting for clinical trials of interventions for heavy menstrual bleeding: Development of a core outcome setes_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doi10.1111/1471-0528.17473
dc.type.hasVersionVoRes_ES


Fichier(s) constituant ce document

[PDF]

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée

Atribución 4.0 Internacional
Excepté là où spécifié autrement, la license de ce document est décrite en tant que Atribución 4.0 Internacional